Trident Lifeline Limited

BSE: TLL · Pharmaceuticals · sector

₹416.95BSE close 2026-10-26

Key numbers

Market cap₹498 cr

Price₹416.95

52w high / low₹425 / ₹230

P/E17.1xSector median 27.9x

P/B5.9xSector median 2.9x

Book value₹71.0

Dividend yield–Sector median 0.48%

ROE41.2%Sector median 11.7%

ROCE54.3%Sector median 12.3%

OPM22.1%Sector median 14.0%

Debt / equity–Sector median 0.16x

EV/EBITDA11.8xSector median 18.6x

Interest cover7.4x

Current ratio1.59x

Sales growth 3y+59.7%Sector median +9.6%

Profit growth 3y+46.9%Sector median +13.3%

PEG0.45x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Operating profit covered interest 7.4x in the last 12 months.
Other income was 51% of net profit in the last 12 months.
No dividend in the last 4 financial years.
Price ₹416.95 on 2026-10-26: -1.9% from the 52-week high, +81.3% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹419.90 · low ₹226.00

Quarterly results

₹ cr	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	50	24	53	26	76	34
EBITDA	9	5	12	5	16	9
OPM %	19.0%	21.9%	22.5%	19.8%	21.3%	25.2%
Other income	4	1	3	5	6	1
Net profit	7	3	8	4	11	5
EPS (₹)	6.32	2.66	6.91	3.72	9.45	4.27
Revenue YoY					+52.5%	+42.8%
Profit YoY					+51.9%	+64.4%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY23	FY24	FY25	FY26	TTM
Revenue	32	45	87	129	188
EBITDA	6	9	15	28	42
Net profit	6	7	12	19	28
EPS (₹)	6.22	6.13	10.22	16.32	24.35
Revenue growth		+40.9%	+94.8%	+48.4%	–
Profit growth		+17.1%	+66.9%	+62.0%	–
Dividend / share (₹)	–	–	–	–

Compounded growth	3 years	5 years	Last 12 months
Sales	+59.7%	–	–
Net profit	+46.9%	–	–
EPS	+37.9%	–	–
Share price	–	+10.1% (2y)	+27.2%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	53	85
Cash & equivalents	2	4
Total assets	156	237
Fixed assets	35	43
Investments	11	8
Inventory	28	36

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	-10	5
Cash from investing	-14	-37
Cash from financing	20	34
Capex	17	36
Free cash flow	-27	-32

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	22.2%	22.5%
ROCE %	33.2%	37.0%
Inventory days	226	174
Working capital days	155	146

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
TLL	₹498 cr	17.1x	5.9x	41.2%	54.3%	22.1%	+59.7%	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	TLL
BSE code	543616
ISIN	INE0MKA01014
Face value	₹10.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.